FGF-23 in bone biology
Open Access
- 15 December 2009
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (4) , 603-608
Abstract
Recent studies have demonstrated that levels of fibroblast growth factor 23 (FGF-23), a key regulator of phosphorus and vitamin D metabolism, rise dramatically as renal function declines and may play a key initiating role in disordered mineral and bone metabolism in patients with chronic kidney disease (CKD). The physiologic importance of FGF-23 in mineral metabolism was first identified in human genetic and acquired rachitic diseases and further characterized in animal models. FGF-23 and its regulators, including phosphate regulating endopeptidase homolog, dentin matrix 1 (DMP1), and matrix extracellular phosphoglycoprotein, are made primarily in bone, specifically in osteocytes. Dysregulation of these proteins results in osteomalacia, implicating the osteocyte in the regulation of skeletal mineralization. Studies in pediatric patients with CKD, the majority of whom have altered skeletal mineralization in early stages of CKD, have demonstrated that skeletal expression of both FGF-23 and its regulator, DMP1, are increased in early stages of CKD and that expression of these proteins is associated with alterations in skeletal mineralization. Thus, dysregulation of osteocytic proteins occur very early in the course of CKD and appear to be central to altered bone and mineral metabolism in this patient population.Keywords
This publication has 55 references indexed in Scilit:
- Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically ActiveThe Journal of Clinical Endocrinology & Metabolism, 2010
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Pathogenic role of Fgf23 in Dmp1-null miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Identification of Full-Length Dentin Matrix Protein 1 in Dentin and BoneCalcified Tissue International, 2008
- Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemiaJournal of Clinical Investigation, 2008
- Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYPEndocrinology, 2007
- The parathyroid is a target organ for FGF23 in ratsJournal of Clinical Investigation, 2007
- Rescue of odontogenesis in Dmp1-deficient mice by targeted re-expression of DMP1 reveals roles for DMP1 in early odontogenesis and dentin apposition in vivoDevelopmental Biology, 2007
- Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolismNature Genetics, 2006
- Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatinBone, 2006